The company’s early-stage trial to test imetelstat — a myelofibrosis medication — was halted by the U.S. Food and Drug Administration in March over concerns about liver toxicity. Geron stock soared on Thursday after the FDA lifted a partial hold on the clinical trial of the drug.
The clinical trial involved 79 patients — 20 of which dropped out — and it examines how effective imetelstat is in treating the blood cancer. The company did not shed any light on why 20 patients dropped out.
Geron also started a company-sponsored clinical trial to evaluate the use of the drug in patients with thrombocythemia and multiple myeloma. The FDA also placed a hold on this trial and has not lifted it.
GERN stock is up over 20% Thursday afternoon.
More Biotech Stock News